Why Do You Keep Gaining Weight Back After Losing It

Medifast promoted Trilivy’s weight-management approach, citing clinical-study results for its Reset 5 & 1 Plan: 98% lean-mass retention and a 14% reduction in visceral fat after 16 weeks. The article describes five potential drivers of weight regain and says the program combines nutrition, coaching, habit support, and a framework targeting fat loss and muscle preservation; it does not report new financial results or market reaction.

Analysis

The investable question is whether Trilivy can improve customer retention and lifetime value—not whether a short-term body-composition result proves durable weight maintenance. The cited 16-week figures are company-reported and, without study design, comparator, sample size, attrition, and follow-up, do not establish a durable advantage or translate directly into lower regain. Coaching and habit support could differentiate Medifast from product-led diets and potentially complement GLP-1 treatment during maintenance; alternatively, medications may substitute for the program or make consumers less willing to pay for it. The second-order effect is therefore a channel-economics test: sustained participation and repeat purchasing must justify the cost of human coaching and customer acquisition.

Near term (days), the release alone is a weak fundamental catalyst; promotional claims may attract attention, but they do not establish incremental demand. Over 1–3 months, watch Medifast’s reported customer trends, revenue, and management commentary for evidence that the repositioning is converting into retention or new enrollment. Over 6–18 months, the thesis depends on whether customers remain engaged after the active weight-loss phase and whether the model works alongside, rather than loses share to, pharmacotherapy. The contrarian risk is treating “metabolic health” positioning as proof of a turnaround before cohort-level outcomes and unit economics are visible. No trade is warranted from this release alone.

Key Decisions for Investors

• No immediate directional position in MED on this announcement; treat it as positioning and product messaging, not evidence of a material earnings inflection.
• Set an alert for the next earnings update: verify enrollment/customer trends, revenue trajectory, and management’s evidence of repeat engagement or maintenance-phase retention. Do not infer those outcomes from the 16-week study claims.
• Before underwriting the efficacy claims, seek the study sample size, control group, measurement definitions, attrition, and longer-term follow-up; absent these, discount the claims as commercial evidence.
• Reassess the competitive thesis if Medifast demonstrates durable retention while serving customers using GLP-1 therapies; conversely, weaker customer metrics or evidence that medication substitutes for its paid program would falsify the potential differentiation case.